138 related articles for article (PubMed ID: 25040481)
21. Andersen Tawil syndrome - periodic paralysis with dysmorphism.
Kamate M; Chetal V
Indian Pediatr; 2011 Jan; 48(1):64-5. PubMed ID: 21317470
[TBL] [Abstract][Full Text] [Related]
22. Andersen-Tawil syndrome presenting as premenstrual periodic paralysis.
Parihar J; Chakraborty P; Kaul B
Muscle Nerve; 2021 Jan; 63(1):E5-E6. PubMed ID: 33094497
[No Abstract] [Full Text] [Related]
23. A peculiar case of palpitations and syncope.
Cheung CC; Scheinman M; Lee BK
Heart Rhythm; 2022 Mar; 19(3):505-507. PubMed ID: 35227417
[No Abstract] [Full Text] [Related]
24. Cardiac characteristics and long-term outcome in Andersen-Tawil syndrome patients related to KCNJ2 mutation.
Delannoy E; Sacher F; Maury P; Mabo P; Mansourati J; Magnin I; Camous JP; Tournant G; Rendu E; Kyndt F; Haïssaguerre M; Bézieau S; Guyomarch B; Le Marec H; Fressart V; Denjoy I; Probst V
Europace; 2013 Dec; 15(12):1805-11. PubMed ID: 23867365
[TBL] [Abstract][Full Text] [Related]
25. Calcium channel blocker and adenosine triphosphate terminate bidirectional ventricular tachycardia in a patient with Andersen-Tawil syndrome.
Sumitomo N; Shimizu W; Taniguchi K; Hiraoka M
Heart Rhythm; 2008 Mar; 5(3):498-9. PubMed ID: 18313615
[No Abstract] [Full Text] [Related]
26. Effects of flecainide on exercise-induced ventricular arrhythmias and recurrences in genotype-negative patients with catecholaminergic polymorphic ventricular tachycardia.
Watanabe H; van der Werf C; Roses-Noguer F; Adler A; Sumitomo N; Veltmann C; Rosso R; Bhuiyan ZA; Bikker H; Kannankeril PJ; Horie M; Minamino T; Viskin S; Knollmann BC; Till J; Wilde AA
Heart Rhythm; 2013 Apr; 10(4):542-7. PubMed ID: 23286974
[TBL] [Abstract][Full Text] [Related]
27. Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
Carrasco JI; Izquierdo I; Medina P; Arnau MÁ; Salvador A; Zorio E
Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1058-9. PubMed ID: 22721569
[No Abstract] [Full Text] [Related]
28. Short QT syndrome: pharmacological treatment.
Gaita F; Giustetto C; Bianchi F; Schimpf R; Haissaguerre M; Calò L; Brugada R; Antzelevitch C; Borggrefe M; Wolpert C
J Am Coll Cardiol; 2004 Apr; 43(8):1494-9. PubMed ID: 15093889
[TBL] [Abstract][Full Text] [Related]
29. Imipramine for incessant ventricular arrhythmias in 2 unrelated patients with Andersen-Tawil syndrome.
Bigelow AM; Khalifa MM; Clark JM
Heart Rhythm; 2015 Jul; 12(7):1654-7. PubMed ID: 25814423
[No Abstract] [Full Text] [Related]
30. A study supporting possible expression of inward-rectifying potassium channel 2.1 channels in peripheral nerve in a patient with Andersen-Tawil syndrome.
Shibuya K; Tsuneyama A; Beppu M; Misawa S; Sekiguchi Y; Amino H; Suzuki YI; Suichi T; Nakamura K; Kuwabara S
Muscle Nerve; 2019 Apr; 59(4):E28-E30. PubMed ID: 30681175
[No Abstract] [Full Text] [Related]
31. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.
Priori SG; Napolitano C; Schwartz PJ; Bloise R; Crotti L; Ronchetti E
Circulation; 2000 Aug; 102(9):945-7. PubMed ID: 10961955
[TBL] [Abstract][Full Text] [Related]
32. Pharmacologic therapy with flecainide for asymptomatic Wolff-Parkinson-White syndrome in an infant with severe left ventricular dyssynchrony.
Suzuki S; Hokosaki T; Iwamoto M
Cardiol Young; 2018 Jul; 28(7):970-973. PubMed ID: 29848398
[TBL] [Abstract][Full Text] [Related]
33. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
Benhorin J; Taub R; Goldmit M; Kerem B; Kass RS; Windman I; Medina A
Circulation; 2000 Apr; 101(14):1698-706. PubMed ID: 10758053
[TBL] [Abstract][Full Text] [Related]
34. Andersen-Tawil syndrome associated with aborted sudden cardiac death: atrial pacing was effective for ventricular arrhythmias.
Kuramoto Y; Furukawa Y; Yamada T; Okuyama Y; Fukunami M
Am J Med Sci; 2012 Sep; 344(3):248-50. PubMed ID: 22739561
[TBL] [Abstract][Full Text] [Related]
35. Multivariate analysis of TU wave complex on electrocardiogram in Andersen-Tawil syndrome with KCNJ2 mutations.
Horigome H; Ishikawa Y; Kokubun N; Yoshinaga M; Sumitomo N; Lin L; Kato Y; Tanabe-Kameda Y; Ohno S; Nagashima M; Horie M
Ann Noninvasive Electrocardiol; 2020 May; 25(3):e12721. PubMed ID: 31724784
[TBL] [Abstract][Full Text] [Related]
36. Obstetric management of a patient with Andersen-Tawil syndrome: A case report.
Inagaki M; Tatsumi T; Yomogita H; Hirose A; Kubo T; Sekiguchi M; Miyasaka N
J Obstet Gynaecol Res; 2021 Jan; 47(1):446-451. PubMed ID: 33205612
[TBL] [Abstract][Full Text] [Related]
37. Kir 2.1 channelopathies: the Andersen-Tawil syndrome.
Tristani-Firouzi M; Etheridge SP
Pflugers Arch; 2010 Jul; 460(2):289-94. PubMed ID: 20306271
[TBL] [Abstract][Full Text] [Related]
38. Combined mexiletine and flecainide for severe long QT syndrome type 3.
Shimizu T; Kawai S; Kawada A; Wakamiya T; Nakano Y; Watanabe S; Iwamoto M
Pediatr Int; 2023 Jan; 65(1):e15517. PubMed ID: 36847291
[No Abstract] [Full Text] [Related]
39. Efficacy of Flecainide in the Treatment of Catecholaminergic Polymorphic Ventricular Tachycardia: A Randomized Clinical Trial.
Kannankeril PJ; Moore JP; Cerrone M; Priori SG; Kertesz NJ; Ro PS; Batra AS; Kaufman ES; Fairbrother DL; Saarel EV; Etheridge SP; Kanter RJ; Carboni MP; Dzurik MV; Fountain D; Chen H; Ely EW; Roden DM; Knollmann BC
JAMA Cardiol; 2017 Jul; 2(7):759-766. PubMed ID: 28492868
[TBL] [Abstract][Full Text] [Related]
40. Flecainide induced ventricular tachycardia (torsades de pointes).
Thevenin J; Da Costa A; Roche F; Romeyer C; Messier M; Isaaz K
Pacing Clin Electrophysiol; 2003 Sep; 26(9):1907-8. PubMed ID: 12930510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
